Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors to purchase 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before deducting expenses.
The offering is expected to close on August 15, 2025, subject to customary closing conditions.
Offering Details
3,225,000 shares of common stock at $1.20 per share.
Proceeds
Expected gross proceeds of $3.9 million.
Closing Date
Expected to close on August 15, 2025.
Placement Agent
Maxim Group LLC is acting as the sole placement agent.
- The offering is being made pursuant to an effective shelf registration statement on Form S-3.
- The shares may be offered only by means of a prospectus which will be available on the SEC's website.
The registered direct offering signifies an opportunity for Scienture Holdings to raise capital for its pharmaceutical operations, reflecting investor confidence in the company's strategic direction.